SNPMiner Trials (Home Page)
Report for Mutation T674I
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 Phase II Study of Crenolanib (CP-868,596), a Selective and Potent Inhibitor of PDGFR, for the Treatment of Patients With Advanced Gastrointestinal Stromal Tumors With the D842-related Mutations and Deletions, Including the D842V Mutation, in the PDGFRA Gene
This Phase II study is designed to evaluate the antitumor efficacy and pharmacokinetics of crenolanib (CP-868,596) in patients with D842-related mutant metastatic GIST.
NCT01243346 D842-related Mutant GIST Drug: Crenolanib besylate (CP-868,596-26), Dose: 140mg BID MeSH:Gastrointestinal Stromal Tumors
HPO:Gastrointestinal stroma tumor
In addition, crenolanib was also active in inhibiting phosphorylation of cell lines with two point mutations (double mutants) PDGFRA V561D + D842V and PDGFRA T674I + D842V. --- V561D --- --- D842V --- --- T674I ---
Primary Outcomes
Description: To determine the response rate of patients with advanced D842V mutant GIST, when treated with Crenolanib (CP-868,596). Response will primarily be determined by RECIST criteria
Measure: The primary end-point is overall response rate Time: 1.5 yearsSecondary Outcomes
Description: To determine the progression free survival rate at 6 months in patients with advanced GIST with the D842V mutation in the PDGFRA gene, when treated with CP-868,596 (crenolanib).
Measure: Progression free survival rate Time: 6 monthsDescription: To obtain additional toxicity information in patients with advanced GIST with the D842V mutation in the PDGFRA gene.
Measure: Obtain toxicity information Time: 1 yearDescription: To obtain additional PK, pharmacodynamic and plasma inhibitory assay information in patients with advanced GIST with the D842V mutation in the PDGFRA gene.
Measure: PKPD analysis Time: 1 year